This study looks at two conditions: iron deficiency and pulmonary hypertension. Iron deficiency means the body does not have enough iron, which is an important mineral needed for many body functions. Pulmonary hypertension is a condition where the blood pressure in the arteries of the lungs is too high, which can make it hard to breathe and do everyday activities. The study will test a treatment called ferric carboxymaltose, which is a medicine that provides iron to the body and is given through a vein. Some patients will receive ferric carboxymaltose while others will receive placebo, which is a substance that looks like the medicine but does not contain the active treatment. The medicine will be given by intravenous injection or infusion, which means it goes directly into a vein.
The purpose of this study is to find out if treating patients who have pulmonary hypertension and iron deficiency with ferric carboxymaltose improves their ability to exercise compared to those who receive placebo. The study will measure this by looking at changes in how far patients can walk in six minutes, which is a common way to check exercise ability in people with heart and lung conditions. The study will also look at other aspects such as quality of life, heart failure symptoms, and fatigue levels to see if the treatment helps patients feel better overall.
During the study, patients will be randomly assigned to receive either ferric carboxymaltose or placebo over a treatment period of up to four weeks. The study is double-blind, which means neither the patients nor the doctors will know who is receiving the actual medicine or placebo during the treatment. Patients will be followed for 24 weeks to see how well the treatment works. The study includes patients with different types of pulmonary hypertension, and all participants must have iron deficiency confirmed by blood tests before joining the study.
Belgium 
